PRR34 as A Potential Drug Target for Various Diseases (G55267)

Target Name: PRR34

NCBI ID: G55267

PRR34

PRR34 as A Potential Drug Target for Various Diseases

PRR34 (C22orf26) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the PRR subfamily of the superfamily of RNA-protein interactions and is involved in the regulation of gene expression.

Recent studies have identified PRR34 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because the protein is involved in the regulation of cellular processes that are disrupted in these conditions, such as the regulation of apoptosis (programmed cell death), cell signaling, and inflammation.

One of the key mechanisms by which PRR34 is involved in these processes is through its role in the regulation of apoptosis. Apoptosis is a natural response of cells to environmental stressors, such as changes in the level of oxygen or nutrients, and is characterized by the release of cellular debris and the clearance of the cells. However, in diseases such as cancer, apoptosis can become misregulated, leading to the development of a cancerous phenotype.

PRR34 is known to play a role in the regulation of apoptosis by promoting the execution of programmed cell death (apoptosis) in response to various stressors. This is done by the formation of a complex between PRR34 and the protein Bcl-2 (B cell lymphoma 2). This complex is involved in the regulation of the expression of genes that are involved in the execution of apoptosis, as well as the delivery of cellular debris to the endoplasmic reticulum (ER) and the clearance of the cells.

Another key role of PRR34 is in the regulation of cell signaling. Signaling is the process by which cells communicate with each other and with their environment in order to generate responses to various stimuli. PRR34 is involved in the regulation of signaling by controlling the activity of enzymes that regulate the formation of protein-protein interaction (PPI) structures, such as the protein-protein interaction between PRR34 and its ligand, PDGF-alpha (Promyelocytic leukemia gene 2).

PRR34 is also involved in the regulation of inflammation. Inflammation is a complex biological response to tissue damage and is characterized by the production of pro-inflammatory cytokines and the recruitment of immune cells to the site of injury or infection. PRR34 is involved in the regulation of inflammation by controlling the activity of enzymes that regulate the production of pro-inflammatory cytokines, such as the nuclear factor kappa B (NF-kB) signaling pathway.

In conclusion, PRR34 is a protein that is involved in a wide range of cellular processes that are disrupted in various diseases. Its role in the regulation of apoptosis, cell signaling, and inflammation makes it a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the mechanisms by which PRR34 is involved in these processes and to develop effective treatments for these diseases.

Protein Name: PRR34 Long Non-coding RNA

The "PRR34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets